| Autor: |
Krista N, Bohlen, Julie M, Kittelsrud, Morgan E, Nelson, Lisa K, Weisser, Neil J, Matthiesen, Julie A, Fieldsend, Nicholas B, Buschette, Leslie L, Cooper, Gareth E, Davies, Erik A, Ehli |
| Rok vydání: |
2020 |
| Zdroj: |
The pharmacogenomics journal. |
| ISSN: |
1473-1150 |
| Popis: |
This study evaluated the timing, use, and clinical outcomes of the GeneFolio® Pharmacogenomic Panel in a healthcare setting with patients managed by primary care providers or by psychiatrists. Participants were randomized to receive a pharmacogenetics report at four weeks or 12 weeks. After DNA collection and genetic analysis, pharmacists produced a recommendation report which was given to providers at the randomization week. The four-week group decreased depression severity (PHQ-9 and BDI) faster than the 12-week group (p = 0.0196), and psychiatrists' patients decreased their depression severity faster than primary care patients (PHQ-9 p = 0.0005, BDI p = 0.0218). Mean mental quality of life increased over time (p 0.0001), but it increased slower for patients taking drugs in the Significant drug-drug-gene interaction category (p = 0.0012). Mental quality of life, depression severity, and clinical outcomes were improved by GeneFolio® pharmacogenomic testing regardless of provider type, with earlier testing improving outcomes sooner. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink